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Background: Surgery is a curative treatment for patients with locally advanced colon cancer, but recurrences are
frequent for those with stage III disease. FOLFOX adjuvant chemotherapy has been shown to improve recurrence-free
survival and overall survival by more than 20% and is nowadays considered a standard of care. However, the vast majority
of patients will not benefit from receiving cytotoxic drugs because they have either already been cured by surgery or
because their tumor cells are resistant to the chemotherapy, for which predictive factors are still not available.
Identifying which patients are unlikely to respond to adjuvant chemotherapy from among those who are eligible for such
treatment would be a major step towards treatment personalization. It would spare such patients from unnecessary
toxicities and would improve the allocation of societal healthcare resources.
Methods/design: PePiTA is a prospective, multicenter, non-randomised trial built on the hypothesis that preoperative
chemosensitivity testing using FDG-PET/CT before and after one course of FOLFOX can identify the patients who are
unlikely to benefit from 6 months of adjuvant FOLFOX treatment for stage III colon cancer.
The study’s primary objective is to examine the ability of PET/CT-assessed tumor FDG uptake after one course of
preoperative chemotherapy to predict the outcome of adjuvant therapy, as measured by 3-year disease-free survival.
Secondary objectives are to examine the predictive value of changes in PET/CT-assessed tumor FDG uptake on overall
survival, to define the best cut-off value of FDG uptake for predicting treatment outcome, and to analyse the
cost-effectiveness of such preoperative chemo-sensitivity testing.
At study planning, exploratory translational research objectives were 1) to assess the predictive value of circulating tumor
cells for disease-free survival, 2) to examine the predictive value of single nucleotide polymorphisms for disease-free
survival with respect to genes related either to toxicity or to drug targets, 3) to assess genomic rearrangements associated
with response or resistance to FOLFOX treatment, 4) to identify an immunologic signature associated with metabolic
tumor response to FOLFOX therapy and, finally, 5) to create a bank of frozen tumor samples for future studies.
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Discussion: PePiTA is the first study to use the primitive tumor chemosensitivity assessed by metabolic imaging as a
guidance for adjuvant therapy in colon cancer. It could pave the way for tailoring the treatment and avoiding useless
toxicities for the patients and inadequate expenses for the society. It could also give an interesting insight into tumoral
heterogeneity, resistance to chemotherapy, genetic predisposants to oxaliplatin toxicity and immune response to cancer.
EudraCT number: 2009-011445-13
Trial registration: ClinicalTrials.gov number, NCT00994864
Keywords: Colon cancer, Adjuvant, Early assessment, Chemosensitivity, FDG-PET, PET/CTBackground
Adjuvant treatment of colon cancer
Colon cancer is a major public health problem accounting
for over one million new cases per year worldwide [1]. Sur-
gery is the only curative therapy available for localised colon
cancer; however, the disease is associated with a significant
recurrence rate for which the depth of tumor penetration
within the intestinal wall and the presence of involved
lymph nodes, as described in the TNM classification system
[2], are major prognostic factors.
In stage III colon cancer, postoperative adjuvant
chemotherapy is associated with a statistically significant
improvement in disease-free survival (DFS) and overall
survival (OS) compared to surgery alone. The National
Surgical Adjuvant Breast and Bowel Project (NSABP) C-01
trial, reported in 1988, was the first study to show such a
survival advantage [3]. Drug regimens were improved
substantially over the years and a 6-month combination of
5 flurouracil (5FU), folinic acid, and oxaliplatin (FOLFOX)
became the reference treatment in 2004 showing a 0.76
hazard ratio (HR) (95% confidence interval [CI] 0.62–0.92)
for relapse favouring FOLFOX compared to fluorouracil
plus folinic acid [4]. In a population of stage II-III colon
cancer, FOLFOX is associated with a 3-year 72.2% DFS and
a 78.5% 5-year survival rate. The current consensus is that
adjuvant chemotherapy is indicated for stage III colon
cancer. However, because of a lower magnitude of benefit,
adjuvant chemotherapy remains controversial for stage II
colon cancer, especially for low-risk patients [5].
Acute toxicity to the FOLFOX regimen in the adjuvant
setting has been well described as moderate to severe
[4], but very little is known with respect to long-term
side effects. With delayed cardiac [6], cognitive [7,8] and
oncogenic [9] side effects increasingly being reported in
cancer survivors treated with adjuvant therapies, long-term
side effects are a major concern associated with every
treatment given with curative intent.
It is challenging to identify which patients are unlikely
to benefit from adjuvant therapy, because no meas-
urement is possible once a tumor has been removed.
Being able to predict this successfully would bring
great benefit, because this would potentially spare
many patients from acute and delayed drug-inducedtoxicities, and avoid the useless spending of public
and private healthcare resources.
Standard response measurements (WHO [10], RECIST
[11], and modified RECIST [12]) rely entirely upon
measuring the size of the tumor with computerized
tomography scan (CT scan), ultrasound or magnetic reson-
ance imaging (MRI) and only apply under restrictive condi-
tions (well defined lesions, adequate minimum size, at least
six weeks of chemotherapy). In the absence of any reliable
chemosensitivity predictors, using such measurements to
determine response means giving potentially ineffective
treatments to patients for long periods of time.
However, early response detection techniques are
now emerging, of which 18 F Fluorodeoxyglucose (FDG)
positron emission tomography (PET)/CT and circulating
tumor cells (CTCs) are the most promising.
Positron emission tomography
The most frequently used tracer for PET/CT in the clinical
setting is FDG, a marker of glycolysis, which is generally
increased in malignant tumors. The uptake of FDG is
related to the viable tumor cell load, and indirectly to the
proliferative activity. PET/CT imaging has been able to
measure a decrease in FDG uptake very early after
exposure to treatment in various settings. In the context
of neoadjuvant treatment of breast cancer, the reduction
of FDG uptake measured at two weeks after the first
dose of chemotherapy has been shown to predict the
late FDG-PET/CT response measured four weeks
after the end of chemotherapy, and to correlate with
histopathological response [13].
A correlation between an early metabolic response
after one or two courses of therapy and patient outcome
has also been found in diffuse large cell lymphoma and
Hodgkin’s disease [14], high-burden follicular lymph-
oma [15], lung cancer [16,17], and locally advanced
oesophagogastric junction tumors treated with neoadjuvant
chemotherapy [18]. In the latter indication, metabolic
imaging-based assessment of response has already been
used to develop trial designs aimed to tailor treatments
according to the level of efficacy [19,20].
In advanced colorectal cancer, reports on the correlation
of patient outcomes with FDG-PET/CT-based metabolic
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are inconsistent [21-23], probably partially because of
methodological issues in multi-metastatic assessment.
Early assessment after one course of therapy seems to be a
more promising approach in light of recent findings that
show excellent negative predictive value in the absence of
morphological response and good correlation with the
overall patient survival [24].
In locally advanced rectal cancer, several independent
research groups have confirmed the high negative
predictive value of metabolic assessment, demonstrating
that the FDG uptake remains unchanged if the tumor is
not sensitive to radio-chemotherapy [25,26].
Circulating tumor cells
CTCs can be detected in the peripheral blood of patients
with advanced tumors and could be useful to monitor
treatment efficacy in metastatic colorectal carcinoma
(CRC) [27-30] and breast cancer [31-33]. A recent
report by Uen et al. suggests an association between
the persistence of CTCs after curative surgery for CRC
and recurrence risk [34]. No data exist concerning their
use in the neoadjuvant setting to monitor therapeutic
response. To assess the potential role of CTCs in locally
advanced colon cancer, we designed a substudy in the
PePiTA trial to analyze the prognostic value of baseline
CTCs and the predictive value of CTC count modifications
after one course of preoperative chemotherapy for adjuvant
therapy outcome.
Single nucleotide polymorphisms
Predicting the toxicity of anti-cancer drugs is complex.
DNA changes (mutations, polymorphisms and gene
hypermethylation) are increasingly implicated in the
observed variation of toxicity among patients. Knowledge
of these characteristics would allow treatments to be
tailored according to individual susceptibility. This point
will be addressed prospectively by performing single
nucleotide polymorphism (SNP) testing before the
preoperative course of chemotherapy.
Genomic rearrangements
Recent advances in next generation sequencing (NGS)
technologies and data analysis have enabled us to
explore specific somatic rearrangements and aberrations
in the cancer genomes of individual patients in a cost
effective and time efficient manner [35]. Tumor cells
releasing naked DNA into blood after apoptosis or necrosis
provide hope for a new approach to cancer detection
through the quantification and analysis of circulating free
DNA. The idea of evaluating blood samples for mutant
DNA is particularly attractive, not only because it could be
used to detect several cancer types, but also because blood
samples can easily be collected during patient follow-up asso-called “liquid biopsy” [36]. If the NGS analysis in this
study demonstrates that the detection and quantification
of specific tumoral genomic rearrangements in circulating
DNA provides a sensitive and specific measure of disease
progression, treatment response and prognosis in patients
with colon cancer, this will have a major impact on the
future clinical treatment of the disease.
Tumor immune infiltration
At present, there are no clinical data available reporting
the immune response (reflected by the type, density and
function of tumor infiltrating lymphocytes (TILs)) of
colon cancer after preoperative chemotherapy. Chemo- and
targeted therapies that potentially stimulate the immune
system [37] or inhibit Treg [38] could modify the immune
infiltration of primary or metastatic tumors. In this regard,
preclinical data (CRC cell lines) suggest that oxaliplatin
induces immunogenic death of CRC cells, and that this
effect determines its therapeutic efficacy in patients with
CRC [39]. Therefore, in this study, particular attention
will be given to the analysis of TILs in tumors resected
after chemotherapy.
Study hypothesis
PePiTA is built on the hypothesis that testing FDG-PET
/CT metabolic changes before and after one course of
FOLFOX given preoperatively will identify the patients
with stage III colon cancer who are most unlikely to have
significant benefit from adjuvant treatment using the same
chemotherapy regimen after surgery for 6 months.
Methods
Study design
PePiTA is a prospective, multicenter, non-randomised trial.
Patients with histologically confirmed colon adenocarcin-
oma compatible with clinical stage III are eligible for study
screening. The study design is illustrated in Figure 1.
Objectives
PePiTA’s primary objective is to examine the ability of
PET/CT-assessed tumor FDG uptake after one course of
preoperative chemotherapy to predict the outcome of
adjuvant therapy, as measured by 3-year DFS among
patients with pathological stage III.
Secondary objectives are to examine the predictive value
of changes in PET/CT-assessed tumor FDG uptake on OS,
to define the best cut-off value of FDG uptake for
predicting treatment outcome, and to analyse the cost-
effectiveness of such preoperative chemosensitivity testing.
Exploratory (translational research) objectives in the con-
text of several sub-studies are 1) to assess the predictive
value of CTCs for DFS, 2) to examine the predictive value
of SNPs for DFS with respect to genes related to toxicity
or drug targets, 3) to assess genomic rearrangements
Figure 1 Study design.
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ment, 4) to identify an immunologic signature associated
with metabolic tumor response to FOLFOX therapy
and, finally, 5) to create a bank of frozen tumor and
blood samples for future translational research studies.
Patient selection criteria
Inclusion criteria
Patients 18 years or older, diagnosed with adenocarcinoma
of the colon compatible at endoscopy examination with a
stage III cancer (invasion of more than one third of the
circumferential colonic lumen) and considered curatively
resectable (R0) based on standard preoperative evaluations,
are eligible for inclusion.
The patients must have good performance status
(WHO performance status 0 or 1), never have received
chemotherapy or pelvic irradiation, have signed informed
consent prior to any study specific procedures, and have
agreed to use effective contraception during the study and
until six months thereafter.
Exclusion criteria
In addition to pregnant or breast-feeding women, excluded
from the study are patients identified with any of the
following conditions or characteristics: suspected metastatic
disease; rectal cancer (located within 15 cm from the anal
verge by endoscopy or under the peritoneal reflection at
surgery); serious illness like inflammatory bowel disease,central nervous system disease, peripheral neuropathy, clin-
ically relevant coronary artery disease, history of myocardial
infarction in the last six weeks, high risk of uncontrolled
arrhythmia, or previous malignancy in the last five years
(except basal-cell carcinoma of the skin or in situ cervical
carcinoma); hypersensitivity to any of the components
of study treatments; major surgical procedure, open
biopsy or significant traumatic injury within 28 days
prior to the study; and having incompletely healed
wounds or anticipating the need for major surgery during
the course of the study.
Treatment
All eligible patients will undergo FDG-PET/CT im-
aging at baseline and then after one cycle of FOLFOX
[3] preoperative chemotherapy (a 2-hour infusion of
200 mg/m2 leucovorin or equivalent, followed by a
bolus of 400 mg/m2 fluorouracil and then a 22-hour
infusion of 600 mg/m2 fluorouracil given on 2 consecutive
days; a two-hour infusion of 85 mg/m2 oxaliplatin on
day 0, simultaneously with leucovorin, using a Y-infusion
device) followed by surgery.
After surgery, patients will be fully evaluable in the
study and receive adjuvant FOLFOX when they meet the
following criteria: the delay between the first PET/CT
scan and the start of neoadjuvant FOLFOX was less
than 7 days; the second PET/CT scan was performed
on D14 (range: D13-D15); postoperative pathology con-
firms stage III (pTNM) adenocarcinoma of the colon;
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than 1.5 × ULN.
All patients, both those meeting the inclusion criteria
only and those fully evaluable for the primary objective,
will be followed for DFS and OS assessment. Time zero
for the assessment of time-to-event outcomes is the first
day of pre-operative chemotherapy. In case a patient dies
or is lost to follow-up before surgery, he or she will be
excluded from the analysis of DFS and OS. The schedule
of assessments is described in Figure 2.
FDG-PET/CT imaging
Whole body static FDG-PET/CT scans will be performed
as described above. The local clinical investigators will be
informed about the results of the baseline FDG-PET/CT.
In case this scan shows suspicion of stage IV disease,
a targeted confirmatory work-up is required before
definite exclusion.
The results of the second FDG-PET/CT will be blinded
to all local clinical investigators until there is formal
documentation of relapse or progression.
Major efforts are undertaken to standardise patient
preparation, FDG-PET/CT acquisition, image reconstruc-
tion, and semi-quantification of FDG uptake. This is
centrally coordinated by the Imaging Core Lab at
Institut Jules Bordet’s Nuclear Medicine Department.
Strict standardisation will ultimately allow reliable pooling
of the FDG-PET/CT imaging data from all participating
centres. All participating FDG-PET/CT centres will beFigure 2 Schedule of assessments.required to adhere to the quality assurance guidelines
defined by the Belgian Hospital Physicists Association,
and to perform a standard phantom (NEMA-type) acqui-
sition, which will ultimately be used for a cross-calibration
of all PET cameras.
The response assessment of the primary tumor will be
performed according to the European Organisation for the
Research and Treatment of Cancer (EORTC) guidelines: a
metabolic response corresponds to a ≥15% decrease of the
standardised uptake value max. In case of the presence
of locoregional lymph node(s) observed on the baseline
FDG-PET/CT, a similar response analysis will be performed
for each lesion separately.
Circulating tumor cells
PePiTA’s CTC substudy aimed to examine the prognos-
tic value of CTCs in colon cancer before and after one
course of preoperative chemotherapy and the predictive
value of changes in CTCs for adjuvant treatment efficacy
after one course of preoperative chemotherapy.
Within 24 hours after collection, 9 ml of peripheral
blood per patient have to be sent at room temperature to
the laboratory responsible for CTC detection. All experi-
ments and evaluations will require the investigators to be
blinded to the clinical status of the patients.
Single nucleotide polymorphisms
PePiTA’s SNP substudy aims to identify molecular
biomarkers to test the value of SNPs 1) to predict
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with clinical toxicity as assessed by NCI-CTCAE v. 3.0, and
2) to predict patient outcome by evaluating genes related to
drug targets.
At each follow-up visit, patients are asked to
complete a questionnaire about chemotherapy-induced
peripheral neuropathy (EORTC QLQ-CIPN20 and
Modified Norris scale).
Before preoperative chemotherapy, one EDTA blood
sample (VenoSafe EDTA-K2) 9 ml has to be obtained
and stored at −80°C and then sent to the laboratory
responsible for SNP analysis.
Candidates for polymorphism genotyping are:
a. Genes related to drug targets: for the platinum
compounds, the DNA repair genes XRCC1, XRCC3,
ERCC1, ERCC2, XPD, hMSH2, MLH1 [40]; for the
antimetabolites 5-FU, capecitabine and pemetrexed,
TYMS [41].
b. Genes related to drug metabolizing enzymes: the
CYP gene family, coding for cytochrome P450
enzymes, and the GST genes, which are linked to
drug resistance and toxicity in platinum drugs and
5-FU/platinum combinations [42,43].
Genomic rearrangements
PePiTA also aims to use NGS technology to identify gen-
omic rearrangements (individual or shared among patients)
associated with response or resistance to preoperative
chemotherapy guided by FDG-PET/CT metabolic imaging
both in tumor tissue and in plasma samples. First, DNA
will be extracted from fresh frozen tissue. Subsequently,
DNA samples will undergo low-coverage whole-genome
sequencing analysis. To follow modifications in tumor-
specific rearrangements (as characterized by NGS) in
the patient over time, circulating DNA will be extracted
from the plasma and patient-specific qPCR protocols
will be developed (Figure 2).
Tumor immune infiltration
The goal of this PePiTA substudy is to identify the
immunologic signature associated with metabolic tumor
response to preoperative FOLFOX therapy in colon cancer.
TILs will be characterized by immunohistochemistry
using markers for specific immune cells including
cytotoxic T lymphocytes, memory T cells, regulatory T
cells, B lymphocytes, and macrophages, amongst others.
Immunohistochemical stainings will be performed on
each resected formalin fixed paraffin embedded (FFPE)
colon cancer tumor, as previously described [44-47]. Next,
cDNA microarray analysis (Affymetrix U133 Plus 2.0) and
RT-qPCR (Taqman) will be realized on frozen tumors
in order to analyze the expression of inflammatory genes,
immunosuppressive genes and genes related to the adaptiveimmune response. Moreover, blood samples will be taken
at several time points during patient follow-up (Figure 2) to
characterize the peripheral blood mononuclear cells via
FACS (fluorescence activated cell sorting) analysis.
Follow-up
Follow-up procedures after completion of adjuvant
treatment have to follow standard European clinical
recommendations for patients with stage II and III
colon cancer: every 3 months for the first 2 years and
every 6 months for the next 3 years. This includes history
and physical examination, serum CEA evaluation, chest
X-ray (CT scan upon suspicion of lung metastases), and
abdominal ultrasound or CT scan. Clinical follow-up data
will be obtained for all patients, including those with stage
II disease, with a minimum follow-up time of three years.
Stage IV diseases discovered at baseline FDG-PET/CT
or during the surgical intervention deemed to remove
the tumor, will not be followed afterwards within the
study scheme.
Tissue bank
A tissue bank will be created from pathological blood
samples and residual tumor samples taken from a surgical
piece, frozen or paraffin embedded, and stored, to permit
future studies with genomic profiling. Both samples from
stage II and stage III tumors will be obtained.
Health economic analysis
Efficient treatment tailoring can improve the allocation of
health care resources by identifying upfront the probability
of patient response to a particular treatment and identifying
subgroups of patients in need of other medical approaches.
A health economic analysis will evaluate the financial
impact of the strategy embodied by PePiTA and intended
to improve the cost effectiveness of adjuvant treatment.
This evaluation will compare the investment in FDG-PET
/CT testing and preoperative FOLFOX with the potential
cost savings and health benefits associated with identifying
patients unlikely to respond to adjuvant chemotherapy.
Quality of life assessment
A generic quality of life assessment (EuroQoL EQ-5D) and
two neuropathy questionnaires (EORTC QLQ-CIPN20 and
Modified Norris Scale) will be completed by patients each
time a response is assessed and upon progression of
disease. The quality of life data will be used to calculate
quality-adjusted life expectancy for the trial population.
Statistical considerations
Using data published by O' Connell and Laurie in patients
with stage II-III colon cancer and a fixed-effects meta-
analytic method, we determined a hazard ratio (HR)
for DFS of 0.63 in favour of adjuvant 5-FU-based
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cause there is no evidence that the benefit of chemo-
therapy is different in stage II than in stage III colon
cancer (Andre et al. did not identify any interaction
between treatment and stage) [4], we hypothesised that
this HR is applicable in a population of patients with
stage III disease only. We further assumed that, for
patients not responding to chemotherapy, the HR equals
1 (no benefit and no harm from chemotherapy).
We derived DFS at 3 years for stage III colon cancer
from the MOSAIC trial (69%) [4]. From the previous
assumptions, we expect DFS at 3 years to be 55% for
non-responders and 83% for responders, in case of a
50% response rate. To detect this anticipated difference,
if true, we need 33 events (α = 5% and β = 10%). To observe
this number of events, we calculated that we needed 135
patients with pathological stage III disease and 225 patients
to be registered in total, hypothesising that 60% of patients
included in the trial will be documented with stage III colon
cancer after surgery.
The trial will be regularly monitored to assess whether
the observations are compatible with the expectations of
50% of eligible patients being assessed as PET responders
after 1 course of FOLFOX and of 60% of screened patients
with stage III. No data analysis about time-to-events
variables will be conducted to make this adjustment.
Discussion
PePiTA is the first study to use the primitive tumor's
chemosensitivity assessed by serial FDG-PET/CT before
and after one course of properative chemotherapy as a
guidance for adjuvant therapy in colon cancer.
If its hypothesis could be demonstrated, this could pave
the way for tailoring the treatment to the patients, avoiding
useless toxicities and inadequate expenses for the society.
This could also give an interesting insight into tu-
moral heterogeneity, resistance to chemotherapy, genetic
predisposants to oxaliplatin toxicity and immune response
to cancer.
The study limitations may be that no fresh biopsy can
be obtained from the patients before initiating therapy,
due to ethical reasons impairing a redo of the diagnostic
colonoscopy, and that therefore genomic analysis will
be made on tumors already exposed to one course of
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